论文部分内容阅读
目的观察匹多莫德联合地氯雷他啶治疗婴幼儿哮喘临床疗效;方法选取到我院就诊的婴幼儿支气管哮喘50例,随机分为对照组与研究组各25例。对照组25例患儿行基础治疗,研究组25例患儿在对照组治疗基础上给予口服匹多莫德联合地氯雷他啶治疗,观察两组治疗前后症状改善情况、临床疗效及不良反应;结果治疗组临床疗效明显优于对照组,差异有统计学意义(P<0.05),研究组的单项症状评分均低于对照组,但统计学分析两组差异无统计学意义(P>0.05);结论匹多莫德联合地氯雷他啶治疗婴幼儿哮喘进行临床观察,结果发现,在降阶梯治疗的基础上,使用匹多莫德联合地氯雷他啶能够有效防治呼吸道感染,减少患儿哮喘发作次数,减轻哮喘发作程度,使哮喘得到理想地控制,在安全性方面较为靠,且有待于更多临床试验进一步探讨。
Objective To observe the clinical efficacy of pidotimod combined with loratadine in the treatment of asthma in infants and young children. Methods Fifty infants with bronchial asthma were randomly divided into control group and study group of 25 cases. Control group of 25 children underwent basic treatment, 25 cases of study group were given pidotimod combined with loratadine treatment on the basis of the control group to observe the two groups before and after treatment to improve the symptoms, clinical efficacy and adverse reactions Results The clinical curative effect of the treatment group was obviously better than that of the control group (P <0.05). The individual symptom scores of the study group were lower than those of the control group, but there was no statistical difference between the two groups ) Conclusion Pidotimod combined with loratadine in the treatment of infant asthma clinical observation and found that on the basis of the step-down treatment, the use of pidotimod combined with loratadine can effectively prevent and treat respiratory infections, reduce Children with asthma attack frequency, reduce the degree of asthma attacks, the asthma was ideally controlled, more reliable in terms of safety, and more clinical trials to be further explored.